{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-042245","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2025-09-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.587402+00:00","generated_at":"2026-05-17T05:58:48.873067+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"C4 Therapeutics Phase 1 cemsidomide shows 50% ORR at 100 µg in RRMM; Phase 2 planned Q1 2026","bullets":["50% ORR at 100 µg and 40% ORR at 75 µg cemsidomide + dex in heavily pre-treated RRMM; median DOR 9.3 mo overall.","No cemsidomide-related discontinuations; minimal dose reductions (6%); low rates of febrile neutropenia (4% Grade 3, 1% Grade 4).","Phase 2 single-arm registrational trial in 4th line+ starts Q1 2026; Phase 1b with BCMA BiTE in 2nd line+ starts Q2 2026.","72 patients enrolled; median 7 prior therapies; 75% had prior CAR-T or T-cell engager therapy; data cutoff July 23, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-042245","json":"https://secwatch.observer/filing/0001628280-25-042245.json","markdown":"https://secwatch.observer/filing/0001628280-25-042245.md","text":"https://secwatch.observer/filing/0001628280-25-042245.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828025042245/0001628280-25-042245-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828025042245/cccc-20250922.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:58:48.873067+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}